Online inquiry

IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ590MR)

This product GTTS-WQ590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Spinal cord injury research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5898MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ1859MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ5723MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9029MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15436MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ6943MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ14388MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ9420MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW